The Pharma Data

JUNE 18, 2021

months; hazard ratio [HR] 0.33 [95% CI 0.25-0.45]); with chlorambucil in combination with obinutuzumab (Obi-Clb; HR 0.85, 95% CI [0.54-1.35]; VENCLYXTO ® (venetoclax) is a first-in-class medicine that selectively binds and inhibits the B-cell lymphoma-2 (BCL-2) protein. After a median follow-up of more than four years (52.4

Medicine 40

Medicine HR Trials Production 40

Pfizer

JANUARY 27, 2023

The authorized adult dosing regimen is expected to result in comparable serum exposures of nirmatrelvir and ritonavir in patients 12 years of age and older and weighing at least 40 kg as observed in adults, and adults with similar body weight were included in the trial EPIC-HR. Accessed: January 2023. Country overview report: week 50 2022.

Marketing 75

Marketing Production Drugs Licensing 75

The Pharma Data

JULY 22, 2021

The approval for this population is based on results from the pivotal Phase 3 KEYNOTE-775/Study 309 trial, in which KEYTRUDA plus LENVIMA demonstrated statistically significant improvements in overall survival (OS), reducing the risk of death by 32% (HR=0.68 [95% CI, 0.56-0.84];

HR 52

HR Trials Dermatology Hormones 52

Pfizer

AUGUST 15, 2022

Cystic fibrosis transmembrane conductance regulator potentiators: lumacaftor/ivacaftor. Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron BA.1 Anticonvulsant: carbamazepine, primidone, phenytoin. Herbal Products: St. John’s Wort (hypericum perforatum). COVID-19, Vaccines. 07.19.2022. COVID-19, Vaccines.

Drugs 99

Drugs Vaccination Vaccine In-Vitro 99

The Pharma Data

JANUARY 20, 2021

Armstrong, cardiologist and Distinguished University Professor of Medicine at the Canadian VIGOUR Centre, University of Alberta, and study chair of the VICTORIA trial. Verquvo met the primary efficacy objective based on a time-to-event analysis (hazard ratio [HR]: 0.90, 95% confidence interval [CI], 0.82-0.98; 0.98; p=0.019).

FDA Approval 52

FDA Approval Production Trials Clinical Trials 52

XTalks

FEBRUARY 5, 2024

It is prescribed for the treatment of metastatic breast cancer in patients with HR-positive/HER2-negative status. Why it did so well: In 2022, Avastin was Roche’s eighth best-selling drug, but as expected, the impact of biosimilars caused the sales of this cancer medicine to decrease by 28 percent compared to 2021.

FDA Approval 101

FDA Approval Drugs Sales Development 101

XTalks

FEBRUARY 22, 2022

Pharmaceutical Regulation. Pharmaceutical regulation ensures the safety and efficacy of drugs and medicinal products for human use. The pharma industry is the most heavily regulated in the world. CNS Safety of Drugs in Late Phase Clinical Trials: Using Cognitive Information in Discussions with Regulators.

Life Science 98

Life Science Clinical Trials Clinical Trials Trials 98

XTalks

FEBRUARY 5, 2024

It is prescribed for the treatment of metastatic breast cancer in patients with HR-positive/HER2-negative status. Why it did so well: In 2022, Avastin was Roche’s eighth best-selling drug, but as expected, the impact of biosimilars caused the sales of this cancer medicine to decrease by 28 percent compared to 2021.

FDA Approval 52

FDA Approval Drugs Sales Development 52

Delveinsight

SEPTEMBER 8, 2021

In the financial domain, the chemical sector, the automobile, and so on, almost every domain consultant are helping with business strategies, management, organization, operational processes, HR, financial advisory, and technology. A pharmaceutical consultant provides companies with expert advice on pharmaceutical development and sales.

Marketing 52

Marketing Production Sales Life Science 52

Pfizer

DECEMBER 20, 2022

The extension of the NDA review period will not impact the Emergency Use Authorization (EUA) or the current availability of the medicine for eligible patients. Cystic fibrosis transmembrane conductance regulator potentiators: lumacaftor/ivacaftor. COVID-19 Medicines Partnerships. In the U.S., approximately 7.6 12.20.2022.

Drugs 69

Drugs Licensing Licensing Containment 69

XTalks

DECEMBER 19, 2023

One of the key factors in its success is its versatility as it is getting approvals for different types of cancers, especially at the advanced stages where other medicines are no longer working. Why it did so well: Revlimid is among one of the best-selling medicines for blood cancer treatment. billion Company: Janssen Biotech, Inc.,

Sales 64

Sales FDA Approval Drugs Vaccination 64

Pfizer

JANUARY 27, 2023

and global regulators for all antiviral products and are carried out by many companies and academic institutions in the U.S. It is important to note that these studies are required by U.S. and around the world. IMPORTANT SAFETY INFORMATION Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5),

Research 112

Research Vaccination Vaccine Drugs 112

Pfizer

DECEMBER 13, 2022

Cystic fibrosis transmembrane conductance regulator potentiators: lumacaftor/ivacaftor. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. COVID-19 Medicines Partnerships. COVID-19 Medicines.

Drugs 110

Drugs Licensing Licensing Production 110

Pfizer

NOVEMBER 23, 2022

Expanding Access to Patent-Protected Medicines in Lower-Income Countries : Launched An Accord for a Healthier World , a first-of-its-kind initiative to enable sustained, equitable access to high-quality medicines and vaccines for 1.2 Pfizer has committed to provide its patent-protected medicines and vaccines available in the U.S.

Licensing 40

Licensing Licensing Drugs Manufacturing 40

The Pharma Data

JUNE 18, 2021

The study met its primary endpoint of superior progression-free survival (PFS) as assessed by an independent review committee (IRC) with a HR 0.216 (95% CI, 0.131-0.357; p < 0.0001), demonstrating a reduction in the risk of disease progression or death for I+V of approximately 78% compared to C+O. vs. 11.4%) (p < 0.0001).

Medicine 52

Medicine Production FDA Approval Trials 52

The Pharma Data

MARCH 3, 2021

LORBRENA has been a transformative medicine for people with ALK-positive advanced NSCLC, and this FDA approval in the first-line setting means that we can now extend hope to even more people.”. Detailed results from the CROWN study were published in the November 2020 issue of the New England Journal of Medicine.

FDA Approval 52

FDA Approval Hormones Trials Medicine 52

The Pharma Data

FEBRUARY 8, 2021

months; hazard ratio [HR] 0.69 [95% CI, 0.58-0.83]; The HR for radiographic progression or death as assessed by blinded independent central review (BICR) was 0.864 [95% CI, 0.718–1.040]. months: HR 0.70 [95% CI, 0.60-0.83]). months: HR 0.70 [95% CI, 0.60-0.83]). 0.83]; p<0.0001).

HR 52

HR In-Vitro Development Clinical Trials 52

XTalks

AUGUST 2, 2023

With each passing year, pharmaceutical companies around the globe strive to deliver cutting-edge medicines, therapies and vaccines that impact the lives of millions. In this in-depth article, we embark on a captivating journey to uncover the top 30 pharma and biotech companies that have been instrumental in shaping the future of medicine.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

JUNE 18, 2021

lead study investigator of the Phase 3 RESONATE-2 trial, and Professor of Medicine at the Wilmot Cancer Institute, University of Rochester. 1 With up to seven years of follow-up, progression-free survival (PFS) benefit with single-agent IMBRUVICA was sustained (Hazard Ratio [HR] 0.160 [95 percent Confidence Interval (CI): 0.111–0.230]).

FDA Approval 40

FDA Approval Medicine Development Trials 40

The Pharma Data

MAY 4, 2021

Internal Medicine. In March 2021, Pfizer announced the publication of complete results from the JADE COMPARE study of its investigational oral, once-daily, Janus kinase 1 (JAK1) inhibitor in The New England Journal of Medicine (NEJM). REVENUES. . . . . . ($ in millions). First-Quarter. . 1,611. . *. *. Rare Disease.

Vaccination 40

Vaccination Vaccine Production Sales 40